Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT80ARU)

• DTT Name: Ganglioside GD2 (GD2)
• Synonyms: Ganglioside G2; GD2
• Gene Name: GD2
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T71164

Molecular Interaction Atlas (MIA) of This DTT

17 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-GD2 CART	DMVQHBK	Neuroblastoma	2D11.2	Phase 2	[1]
APN301	DMGNFBC	Neuroblastoma	2D11.2	Phase 2	[2]
Hu3F8 mAb	DM9MKQ5	Neuroblastoma	2D11.2	Phase 2	[3]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[4]
4SCAR-GD2	DMEGSU5	Tumour	2A00-2F9Z	Phase 1/2	[5]
CAR-T cells targeting CD2	DMJVENR	Cervical cancer	2C77.0	Phase 1/2	[6]
CAR-T cells targeting GD2	DMFCPG0	Glioma	2A00.0	Phase 1/2	[7]
GD2-CART01	DM5VF04	Neuroblastoma	2D11.2	Phase 1/2	[8]
Anti-GD2 T-cells (1RG-CART)	DMBVUFL	Neuroblastoma	2D11.2	Phase 1	[9]
Anti-GD2-CAR engineered T cells	DMCNFZG	Neuroblastoma	2D11.2	Phase 1	[10]
C7R-GD2.CART cells	DMSO3JA	Neuroblastoma	2D11.2	Phase 1	[11]
GD2 T cells	DM9TD2N	Neuroblastoma	2D11.2	Phase 1	[12]
IC9-GD2-CD28-OX40	DMRYHWA	Neuroblastoma	2D11.2	Phase 1	[13]
IC9.GD2.CAR.IL-15 T-cells	DMMPFZO	Neuroblastoma	2D11.2	Phase 1	[14]
KUR-501	DMKMN5R	Neuroblastoma	2D11.2	Phase 1	[15]
MVT-5873	DMEJ4C1	Colorectal cancer	2B91.Z	Phase 1	[3]
GD2-targeted CAR-T cells	DM87BTM	Neuroblastoma	2D11.2	Clinical trial	[16]

References

• [1] ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
• [2] Clinical pipeline report, company report or official report of Apeiron Biologics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [5] ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
• [6] ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
• [7] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [8] ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
• [9] ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
• [10] ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
• [11] ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N)
• [12] ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
• [13] ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
• [14] ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma
• [15] Clinical pipeline report, company report or official report of Kuur Therapeutics.
• [16] ClinicalTrials.gov (NCT02919046) Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children